Myeloperoxidase‐Antibody Positivity and Progression to Microscopic Polyangiitis in Interstitial Lung Disease: A Case Series
Abstract
Microscopic polyangiitis (MPA) is associated with myeloperoxidase‐antibody positivity and pulmonary complications. However, these antibodies may be found incidentally in some people with interstitial lung disease (ILD). As a result, management of people with ILD and myeloperoxidase‐antibody positivity remains unclear. Our case series describes the natural history of this group of patients over a mean follow‐up period of 4 years. Using data from a public sector pathology provider in Western Australia, we identified 17 people with a positive myeloperoxidase‐antibody titre and who attended our tertiary Respiratory outpatient clinic. Eventual or concurrent diagnosis of MPA was more common in those with radiological usual interstitial pneumonia pattern, higher baseline and peak myeloperoxidase‐antibody titres, lower gas transfer capacity and lower distances achieved on 6‐min walk testing. These features may be used by clinicians during multidisciplinary team discussion to identify those at high‐risk of developing MPA.
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health. Reported size: 17 participants or records.
Read the paper
Related studies
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Tocilizumab in patients with severe COVID-19: a retrospective cohort study
- A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A cohort study
- Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study
- Are noise and air pollution related to the incidence of dementia? A cohort study in London, England
- Long COVID symptoms and duration in SARS-CoV-2 positive children — a nationwide cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.